India built a wall around Penicillin G. It expires in January.
Last week's brief argued that India's Production Linked Incentive scheme succeeded where chemistry was cheap and failed where it was fermentation. Seven of the eight bulk drugs still without a domestic project are fermentation-based. The one large fermentation success, Penicillin G, needed something beyond the incentive to survive.
This is that something, and it is more specific and more temporary than I expected.
What was actually done
On 29 January 2026 the Directorate General of Foreign Trade issued Notification No. 56/2025-26, setting a minimum import price on three antibiotic inputs:
| Product | ITC HS code | Minimum import price |
|---|---|---|
| Penicillin G potassium | 29411010 | ₹2,216 per kg |
| Amoxicillin Trihydrate | 29411030 | ₹2,733 per kg |
| 6-APA | 29411050 | ₹3,405 per kg |
Imports below those prices are moved from "Free" to "Restricted". Above them, nothing changes. This is not a duty and not a quota. It is a floor: you may import as much as you like, provided you do not import it cheaply.
Aurobindo Pharma, through Lyfius Pharma, is the company on the other side of that floor. It holds the PLI approval for Penicillin G and said in February that it expects capacity to reach 10,000 tonnes a year within twelve months.
So the sequence is: incentive awarded, plant built, plant starts producing, and then a price floor appears to stop cheaper Chinese material undercutting it. Capacity on its own was not enough to make the economics work. That was the argument last week and the policy record now supports it explicitly.
Two things in the notification that matter more than the headline
It runs for one year. The MIP applies for twelve months from publication, which means it lapses on 29 January 2027 unless it is renewed.
A fermentation plant at that scale is a fifteen to twenty year asset. The protection standing between it and Chinese pricing has a four month remaining life as I write this. Renewal is plausible, perhaps likely, but it is not automatic and it is not in the notification. Anyone modelling the economics of Indian Penicillin G past January is modelling a policy decision that has not been made.
That is the question I would want answered if I were financing, supplying or competing with that plant, and I have not seen it asked anywhere.
It exempts most of the people importing. The restriction does not apply to imports by hundred percent Export Oriented Units, units in Special Economic Zones, or imports under the Advance Authorisation Scheme, provided the inputs are not sold into the domestic tariff area.
India's antibiotic formulators export heavily. Under these carve-outs, a formulator producing for export can continue buying Chinese Penicillin G at whatever price it is offered. The floor binds only on material destined for the Indian domestic market.
So the wall is narrower than the headline suggests. It protects the domestic price of Indian Penicillin G. It does not, by design, protect the domestic producer from Chinese competition in the export-oriented segment, which is where a large share of the volume sits.
Whether that was the intention or the price of getting the notification issued at all, I do not know. It is a real limit on how much the measure can do.
What this says about the other seven
Last week's eight are the fermentation products nobody bid for. The implicit question was what it would take to change that.
We now have a partial answer, and it is not encouraging for them. Making one fermentation product viable required a PLI award, a very large integrated manufacturer willing to build, and then a bespoke trade measure issued separately, aimed at three specific HS codes, limited to twelve months, with carve-outs.
That is not a template that scales to seven more molecules. Each would need its own notification, its own price discovery, its own renewal fight. Neomycin, Gentamycin, Streptomycin, Tetracycline and Clindamycin Base have no plant for a floor to protect, so the measure is not even available to them in the order it was used here. The capacity has to exist first.
Which returns the question to where it started. If the scheme could not attract a bidder for these products, and the protection instrument only becomes usable after somebody has already built, what is the mechanism by which that first plant gets built?
What I am watching
Whether Notification 56/2025-26 is renewed before 29 January 2027, and on what terms. A renewal at the same prices, a renewal at revised prices, or a lapse are three quite different signals about how the government reads the plant's competitiveness.
Whether the carve-outs are narrowed. If export-oriented importers are brought inside the floor, that is a much stronger measure than what exists today.
Whether the same instrument appears for any other bulk drug.
Those three HS codes are now in the tracker with this notification as their source.
Sources. DGFT Notification No. 56/2025-26, dated 29 January 2026, minimum import price on Penicillin G potassium, Amoxicillin Trihydrate and 6-APA. Aurobindo Pharma capacity guidance as reported February 2026. PLI approval for Penicillin G to Aurobindo Pharma via Lyfius Pharma, Department of Pharmaceuticals approved applicant list.
Note on confidence. The notification details, HS codes and prices are from the notification itself. The reading of the exemptions and their practical effect is my analysis and I would welcome correction from anyone who imports under these codes.
Feedstock India does not provide investment advice and makes no recommendation regarding any security.